Aromatase Inhibitor class drugs
7 results
Anastrozole (anastrozole tablets)
(Anastrozole Tablets)Upsher-Smith Laboratories, LLC
Usage: Anastrozole is indicated for the adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women, as well as for first-line and second-line treatments of locally advanced or metastatic breast cancer. It is effective following disease progression after tamoxifen therapy.
Anastrozole (anastrozole)
(Anastrozole)American Health Packaging
Usage: Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, first-line treatment of hormone receptor-positive or unknown locally advanced or metastatic breast cancer, and second-line treatment of advanced breast cancer following disease progression on tamoxifen therapy.
Anastrozole (anastrozole)
(Anastrozole)Natco Pharma Limited
Usage: Anastrozole tablets are indicated for adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer, as well as for first-line treatment of hormone receptor-positive or unknown locally advanced or metastatic breast cancer. It is also used as a second-line treatment for advanced breast cancer after tamoxifen therapy.
Anastrozole (anastrozole)
(Anastrozole)Zydus Lifesciences Limited
Aromasin (exemestane)
(exemestane)Pharmacia & Upjohn Company LLC
Usage: AROMASIN is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer after 2-3 years of tamoxifen, completing a total of 5 years of therapy. It is also used for advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.
Exemestane (exemestane)
(Exemestane)Zydus Lifesciences Limited
Exemestane (exemestane)
(Exemestane)Hikma Pharmaceuticals USA Inc
Usage: Exemestane is indicated for the adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer after two to three years of tamoxifen. It is also used for treating advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy.